Combined Pharmacologic Inhibition of MEK-ERK and PI3K/mTOR Signaling in Glioblastoma Models Enhances Therapeutic Antitumor Activity

被引：0
|
作者：
Schreck, Karisa [1 ]
Allen, Amy [1 ]
Wang, Jiawen [1 ]
Pratilas, Christine [1 ]
机构：
[1] Johns Hopkins Sch Med, Baltimore, MD USA
来源：
NEUROLOGY | 2019年 / 92卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P2.6-023
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models
    Roberts, Patrick J.
    Usary, Jerry E.
    Darr, David B.
    Dillon, Patrick M.
    Pfefferle, Adam D.
    Whittle, Martin C.
    Duncan, James S.
    Johnson, Soren M.
    Combest, Austin J.
    Jin, Jian
    Zamboni, William C.
    Johnson, Gary L.
    Perou, Charles M.
    Sharpless, Norman E.
    CLINICAL CANCER RESEARCH, 2012, 18 (19) : 5290 - 5303
  • [2] Pharmacologic Inhibition of MEK-ERK Signaling Enhances Th17 Differentiation
    Tan, Andy Hee-Meng
    Lam, Kong-Peng
    JOURNAL OF IMMUNOLOGY, 2010, 184 (04): : 1849 - 1857
  • [3] Hijacking the PI3K/mTor and KRas/MEK/ERK signaling pathways with a therapeutic assault results in robust antitumor activity in PI3K/KRas and KRas mutant tumors
    Vincent, Loic
    Thomas, Anne
    Ma, Jianguo
    Clark, Anderson
    Shaw, Jamie
    Guerif, Stephane
    Egile, Coumaran
    Lager, Joanne
    Debussche, Laurent
    Lengauer, Christoph
    Garcia-Echeverria, Carlos
    Ogden, Janet A.
    CANCER RESEARCH, 2011, 71
  • [4] Combined PI3K-AKT and MEK-ERK pathway inhibition provides broad antitumor efficacy in HER2+breast tumor models
    De, Pradip
    Sun, Yuliang
    Carlson, Jennifer
    Friedman, Lori
    Dey, Nandini
    Leyland-Jones, Brian
    CANCER RESEARCH, 2014, 74 (19)
  • [5] Parallel Signaling through PI3K/AKT/mTOR Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition
    Ricciardi, Maria Rosaria
    Tsao, Twee
    Abrams, Stephen Lee
    Bergamo, Paola
    Steelman, Linda S.
    Decandia, Samantha
    Felicioni, Lara
    Ciuffreda, Ludovica
    Di Sanza, Cristina
    Marchetti, Antonio
    Cognetti, Francesco
    McCubrey, James
    Konopleva, Marina
    Andreeff, Michael
    Tafuri, Agostino
    Milella, Michele
    BLOOD, 2009, 114 (22) : 246 - 247
  • [6] Therapeutic Resistance Resulting From Mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Signaling Pathways
    McCubrey, James A.
    Steelman, Linda S.
    Kempf, C. Ruth
    Chappell, William H.
    Abrams, Stephen L.
    Stivala, Franca
    Malaponte, Graziella
    Nicoletti, Ferdinando
    Libra, Massimo
    Baesecke, Joerg
    Maksimovic-Ivanic, Danijela
    Mijatovic, Sanja
    Montalto, Giuseppe
    Cervello, Melchiorre
    Cocco, Lucio
    Martelli, Alberto M.
    JOURNAL OF CELLULAR PHYSIOLOGY, 2011, 226 (11) : 2762 - 2781
  • [7] A PI3K inhibitor-induced growth inhibition of cancer cells is linked to MEK-ERK pathway
    Duff, Angela
    Kavege, Llona
    Baquier, Jocelyn
    Hu, Tang
    ANTI-CANCER DRUGS, 2021, 32 (05) : 517 - 525
  • [8] Identifying a mechanism of acquired resistance to the combined inhibition of PI3K/mTOR and MEK in colorectal carcinoma
    Garza, Scott J.
    Lira, Paul
    Huang, Stephen D.
    Cheng, Hengmiao
    Dann, Stephen G.
    VanArsdale, Todd L.
    Fantin, Valeria
    Christensen, James
    Kan, Julie L.
    CANCER RESEARCH, 2014, 74 (19)
  • [9] PTEN loss as a putative biomarker of synergistic growth inhibitory activity of combined MEK/ERK and PI3K/mTOR pathway blockade
    Ciuffreda, Ludovica
    Falcone, Italia
    Matteoni, Silvia
    Sacconi, Andrea
    Malusa, Federico
    Luca, Teresa D.
    Incani, Ursula Cesta
    Del Curatolo, Anais
    Konopleva, Marina
    Andreeff, Michael
    Eramo, Adriana
    Maria, Ruggero D.
    Del Bufalo, Donatella
    Cognetti, Francesco
    Milella, Michele
    CANCER RESEARCH, 2014, 74 (19)
  • [10] Synergistic antitumor effect of BRMS1 and sorafenib via inhibition of the PI3K/AKT/mTOR/ERK signaling pathway
    Jin, Jingyun
    Guo, Yonggang
    Liu, Yang
    Wang, Zhenguo
    Yang, Xiaosa
    Sun, Shengkai
    ONCOLOGY REPORTS, 2019, 42 (03) : 1183 - 1193
12345